drug_type
RELEVANT_DRUG
intervention_type
Bispecific monoclonal antibody (T-cell costimulatory)
drug_description
Investigational EGFR×CD28 bispecific antibody that binds EGFR on tumor cells and CD28 on T cells to provide conditional costimulation and amplify T-cell activation with PD-1 blockade.
nci_thesaurus_concept_id
C178284
nci_thesaurus_preferred_term
Dalmitamig
nci_thesaurus_definition
A bispecific antibody directed against both human epidermal growth factor receptor (EGFR) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, dalmitamig binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and EGFR found on EGFR-expressing tumor cells. This activates and redirects CTLs to EGFR-expressing tumor cells, which may result in the CTL-mediated cell death of EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Dalmitamig (REGN7075) is a bispecific antibody that binds EGFR on tumor cells and CD28 on T cells, delivering tumor-targeted CD28 costimulation to enhance and redirect T-cell activation and cytotoxicity against EGFR-expressing tumor cells, with synergy alongside PD-1 blockade.
drug_name
REGN7075
nct_id_drug_ref
NCT06465329